Luminogenic cytochrome P450 assays

• WRIGHTON SA, STEVENS JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Tox. (1992) 22(1):1-21.
   PubMed Web of Science ®Google Scholar
• BJORNSSON TD, CALLAHAN JT, EINOLF HJ etal.: The conduct of invitro and invivo drugdrug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. (2003) 31(7):815-832.
   PubMed Web of Science ®Google Scholar
• PELKONEN O: Human CYPs: invivo and clinical aspects. Drug Metab. Rev. (2002) 34(1&2):37-46.
   PubMed Web of Science ®Google Scholar
• WEINKERS LC, HEATH GH: Predicting invivo drug interactions from invitro drug discovery data. Nat. Rev. Drug Disc. (2005) 4:825-833.
   PubMed Web of Science ®Google Scholar
• ZLOKARNIK G, GROOTENHUIS PDJ, WATSON JB: High throughput P450 screens in early drug discovery. Drug Disc. Today (2005) 10(21):1443-1450.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN MA, WOODCOCK JL, LUMPKIN MM, SHUREN JE, HASS AE, THOMPSON LJ: The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA (1999) 281(18):1728-1734.
   PubMed Web of Science ®Google Scholar
• LIN JH: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. (1995) 23(10):1008-1021.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JA, HYLAND R, JONES BC etal.: Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab. Dispos. (2004) 32(11):1201-1208.
   PubMed Web of Science ®Google Scholar
• FURGE LL, GUENGERICH FP: Cytochrome P450 enzymes in drug metabolism and chemical toxicity. Biochem. Mol. Biol. Ed. (2006) 34(2):66-74.
   PubMed Web of Science ®Google Scholar
• VERMIER M, ANNAERT P, MAMIDIRNVS, ROYMANS D, MEULDERMANS W, MANNENS G: Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin. Drug Metab. Toxicol. (2005) 1(1):75-90.
   PubMedGoogle Scholar
• YUEY M-F, KAWAHARA M, RAUCY J: High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos. (2005) 33(1):38-48.
   PubMed Web of Science ®Google Scholar
• MILLS BM, ROSE KA, SADAGOPAN N, SAHI J, MORAIS SMF: Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharm. Exp. Ther. (2004) 309(1):303-309.
   PubMed Web of Science ®Google Scholar
• KELLY JH, SUSSMAN NL: A fluorescent cell-based assay for cytochrome P450 isozyme 1A2 induction and inhibition. J. Biomol. Screen. (2000) 5(4):249-254.
   PubMed Web of Science ®Google Scholar
• MADAN A, GRAHAM RA, CARROLLKM etal.: Effects of prototypical enzyme inducers on cytochrome P450 expression in cultured hepatocytes. Drug Metab. Dispos. (2003) 31(4):421-431.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, KLIEWER SA: PXR, CAR and drug metabolism. Nat. Rev. Drug Disc. (2002) 1:259-266.
   PubMed Web of Science ®Google Scholar
• FERGUSON SS, CHEN Y, LECLUYSEEL, GOLDSTEIN JA: Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4-. Mol. Pharmacol. (2005) 68(3):747-757.
   PubMed Web of Science ®Google Scholar
• CHEN Y, FERGUSON SS, NEGISGI M, GOLDSTEIN JA: Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol. (2003) 64(2):316-324.
   PubMed Web of Science ®Google Scholar
• NEBERT DW, ROE AL, DIETER MZ, SOLIS WA, YANG Y, DALTON TP: Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharm. (1999) 59:65-85.
   Web of Science ®Google Scholar
• SAVAS U, HSU MH, JOHNSON EF: Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch. Biochem. Biophys. (2003) 409(1):212-220.
   PubMed Web of Science ®Google Scholar
• TANG W, WANG RW, LU, AYH: Utility of recombinant cytochrome P450 enzymes: a drug metabolism perspective. Curr. Drug Metab. (2005) 6:503-517.
   PubMed Web of Science ®Google Scholar
• SEGEL IH: Enzyme kinetics. John Wiley & Sons, Canada (1975).
   Google Scholar
• ITO K, IWATSUBO T, KANAMITSU S, NAKAJIMA Y, SUGIYAMA Y: Quantitative prediction of invivo drug clearance and drug interactions from invitro data on metabolism, together with binding and transport. Ann. Rev. Pharmacol. Toxicol. (1998) 38:461-499.
   PubMed Web of Science ®Google Scholar
• BRANCHINI BR, MAGYAR RA, MURTIASHAW MH, ANDERSON SM, ZIMMER M: Site-directed mutagenesis of histidine 245 in firefly luciferase: a proposed model of the active site. Biochemistry (1998) 37(44):15311-15319.
   PubMed Web of Science ®Google Scholar
• WORZELLA T, LARSON B, CALI J, GALLAGHER A, MATTHEWS E: Miniaturizing luminescent P450-GloTM assays for HTS. Cell Notes (2004) 10:6-8.
   Web of Science ®Google Scholar
• GUENGERICH FP: Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. (2001) 14(6):611-650.
   PubMed Web of Science ®Google Scholar
• CALI JJ, HO S, MA D etal.: Bioluminescent P450 assays that use D-luciferin derivatives as substrates for CYP1A1, 1A2, 1B1, 2C8, 2C9, 2J2, 3A4, 3A7, 4A11, 4F3B, 4F12 and 19. Proceedings of the 14th International Conference on Cytochrome P450s Medimond S.r.l. International Proceedings. (2005):77-84.
   Google Scholar
• CALI JJ, SOBOL M, MA D, GOOD T, LIU D: P450-GloTM CYP2C19 and CYP2D6 assays. Cell Notes (2006) 14:20-24.
   Google Scholar
• GUO Y, WANG Y, SI D, FAWCETT PJ, ZHONG D, ZHOU H: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica (2005) 35(9):853-861.
   PubMed Web of Science ®Google Scholar
• ANZENBACHEROVA E, VEINLICHOVA A, MASEK V ANZENBACHER P: Comparison of high throughput micromethods for determination of cytochrome P450 activities with classical methods using HPLC for product identification. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. (2005) 149(2):353-355.
   PubMedGoogle Scholar
• UENG Y-F, KUWABARA T, CHUN Y-J, GUENGERICH FP: Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry (1997) 36:370-381.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA M, INOUE T, SHIMADA N, TOKUDOME S, YAMAMOTO T, KUROIWA Y: Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab. Dispos. (1998) 26(3):261-266.
   PubMed Web of Science ®Google Scholar
• WHITLOCK JP: Induction of cytochrome P4501A1. Ann. Rev. Pharmacol. Toxicol. (1999) 39:103-125.
   PubMed Web of Science ®Google Scholar
• HALL MP, GRUBER MG, HANNAH RR, JENNENS-CLOUGH ML, WOOD KV: Stabilization of firefly luciferase using directed evolution. In: Bioluminescence and Chemiluminescence: Perspectives for the 21st Century. A Rode, M Pazzagli, LJ Kricka, PE Stanley (Eds.), John Wiley & Sons, Chichester (1998):392-395.
   Google Scholar
• MANCY A, ANTIGNAC M, MINOLETTI C etal.: Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry (1999) 38:14264-14270.
   PubMed Web of Science ®Google Scholar
• GRANVIL CP, KRAUSZ KW, GELBOINHV, IDLE JR, GONZALEZFJ: 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J. Pharmacol. Exp. Ther. (2002) 301(3):1025-1032.
   PubMed Web of Science ®Google Scholar
• STRESSER DM, BLANCHARD AP, TURNER SD etal.: Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos. (2000) 28(12):1440-1448.
   PubMed Web of Science ®Google Scholar
• OBACH RS: Nonspecific binding to microsomes: impact on scale-up of invitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. (1997) 25(12):1359-1369.
   PubMed Web of Science ®Google Scholar
• AUSTIN RP, BARTON P, MOHMED S, RILEY RJ: The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. (2005) 33(3):419-425.
   PubMed Web of Science ®Google Scholar
• ZHANG J-H, CHUNG TDY, OLDENBURG KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Scr. (1999) 4:67-73.
   PubMed Web of Science ®Google Scholar
• BOSETTI A, SOBOL S, MA D, GOODT, LIU D, CALI JJ: Bioluminescent cytochrome P450 assays. Pharmacologyonline (2005) 3:9-18.
   Google Scholar
• WANG RW, NEWTON DJ, LIU N, ATKINS WM, LU AYH: Human cytochrome P450 3A4: invitro drugdrug interactions patterns are substrate-dependent. Drug Metab. Dispos. (2000) 28(3):360-366.
   PubMed Web of Science ®Google Scholar
• HOSEA NA, MILLER GP, GUENGERICH FP: Elucidation of distinct binding sites for cytochrome P450 3A4. Biochemistry (2000) 39:5929-5939.
   PubMed Web of Science ®Google Scholar
• HUTZLER JM, HAUER MJ, TRACY TS: Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. (2001) 29(7):1029-1034.
   PubMed Web of Science ®Google Scholar
• KERDPIN O, ELLIOT DJ, BOYE SL, BIRKETT DJ, YOOVATHAWORN K, MINERS JO: Differential contributions of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry (2004) 43(24):7834-7842.
   PubMed Web of Science ®Google Scholar
• DOMANSKI TL, HE Y-A, KHAN KK, ROUSSEL F, WANG Q, HALPERT JR: Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry (2001) 40:10150-10160.
   PubMed Web of Science ®Google Scholar
• TESTINA SA Jr, PATONAY G: High-throughput inhibition screening of major human cytochrome P450 enzymes using an invitro cocktail and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. (2003) 30(5):1459-1467.
   PubMed Web of Science ®Google Scholar
• WEAVER R, GRAHAM KS, BEATTIEIG, RILEY RJ: Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. (2003) 31(7):955-966.
   PubMed Web of Science ®Google Scholar
• MOODY GC, GRIFFIN SJ, MATHERAN, McGINNITY DF, RILEYRJ: Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica (1999) 29(1):53-75.
   PubMed Web of Science ®Google Scholar
• DELAPORTE E, SLAUGHTER DE, EGAN MA etal.: The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. J. Biomol. Screen. (2001) 6(4):225-231.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, HANNA IH, CAI H, NISHIMURA Y, WILLIAMS KM, GUENGERICH FP: Coumarin substrates for cytochrome P450 2D6 fluorescence assays. Anal. Biochem. (2001) 292:280-286.
   PubMed Web of Science ®Google Scholar
• REINERS JJ, CANTU AR, PAVONE A, SMITH SC, GARDNER CR, LASKINDL: Fluorescnece assay for per-cell estimation of cytochrome P450-dependent monooxygenase activitities in keratinocyte suspensions and cultures. Anal. Biochem. (1990) 188:317-324.
   PubMed Web of Science ®Google Scholar
• SPORTSMAN JR, LEE SK, DILLEY H, BUKAR R: Fluorescence polarization. High throughput screening: the discovery of bioactive substances. JP Devlin (Ed.), Marcel Dekker, Inc. New York, NY, USA (1997):389-399.
   Google Scholar
• SINGH P, LILLYWHITE B, BANNAGHAN C, BROAD P: Using IMAP technology to identify kinase inhibitors: comparison with a substrate depletion approach and analysis of the nature of false positives. Comb. Chem. High Throughput Screen. (2005) 8(4):319-325.
   PubMed Web of Science ®Google Scholar
• SAI Y, DAI R, YANG TJ etal.: Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica (2000) 30(4):327-343.
   PubMed Web of Science ®Google Scholar
• CHANG TKH, GONZALEZ FJ, WAXMAN DJ: Evaluation of triacetyloleandomycin, -naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. (1994) 311(2):437-442.
   PubMed Web of Science ®Google Scholar
• STRESSER DM, BROUDY MI, HO T etal.: Highly selective inhibition of human CYP3A invitro by azamulin and evidence that inhibition is irreversible. Drug Metab. Dispos. (2004) 32(1):105-112.
   PubMed Web of Science ®Google Scholar
• OLESEN OV, LINNET K: Fluvoxamineclozapine drug interaction: inhibition invitro of five cytochrome P450 isoforms involved in clozapine metabolism. J. Clin. Psychopharmacol. (2000) 20(1):35-42.
   PubMed Web of Science ®Google Scholar
• CRESPI CL, MILLER VP, PENMAN BW: Microtiter plate assays for inhibition of human, drug-metabolizing cytochrome P450. Anal. Biochem. (1997) 248:188-190.
   PubMed Web of Science ®Google Scholar
• GAO F, JOHNSON DL, EKINS S etal.: Optimizing higher throughput methods to assess drugdrug interactions for CYP1A2, CYP2C9, CYP 2C19, CYP2D6, rCYP2D6, and CYP3A4 invitro using a single point IC50. J. Biomol. Screen. (2002) 7(4):373-382.
   PubMed Web of Science ®Google Scholar
• YIN H, RACHA J, LI S-Y, OLEJNIK N, SATOH H, MOORE D: Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica (2000) 30(2):141-154.
   PubMed Web of Science ®Google Scholar
• ATTAR M, DONG D, LING K-HJ, TANG-LIU DD-S: Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab. Dispos. (2003) 31(4):476-481.
   PubMed Web of Science ®Google Scholar
• WEN X, WANG J-S, BACKMAN JT, LAITILA J, NEUVONEN PJ: Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. (2002) 30(6):631-635.
   PubMed Web of Science ®Google Scholar
• BACK DJ, TJIA JF, KARBWANG J COLBERT J: Invitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharm. (1988) 26:23-29.
   PubMed Web of Science ®Google Scholar
• WEAVER R, GRAHAM KS, BEATTIEIG, RILEY RJ: Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. (2003) 31(7):955-966.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI H, SUZUKI M, TANE K, SHIMADA N, NAKAJIMA M, YOKOI T: Invitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica (2000) 30(1):61-70.
   PubMed Web of Science ®Google Scholar
• DESTA Z, SOUKHOVA NV, FLOCKHART DA: Inhibition of cytochrome P450 (CYP450 isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. (2001) 45(2):382-392.
   PubMed Web of Science ®Google Scholar
• LIU KH, KIM MJ, SHON JH etal.: Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole invitro. Xenobiotica (2005) 35(1):27-38.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, SUZUKI A, KOHNO Y: High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica (2003) 33(8):823-839.
   PubMed Web of Science ®Google Scholar
• MARTINEZ C, AGUNDEZ JAG, GERVASINI G, MARTIN R, BENITEZ J: Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics (1997) 7:85-93.
   PubMedGoogle Scholar
• KARIV I, FERESHTEH MP, OLDENBURG KR: Development of a miniaturized 384-well high throughput screen for detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J. Biomol. Screen. (2001) 6(2):91-99.
   PubMed Web of Science ®Google Scholar
• DELAPORTE E, SLAUGHTER DE, EGAN MA etal.: The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. J. Biomol Screen. (2001) 6(4):225-231.
   PubMed Web of Science ®Google Scholar
• MA B, PRUEKSARITANONT T, LIN JH: Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. (2000) 28(2):125-130.
   PubMed Web of Science ®Google Scholar
• RACHA JK, ZHAO ZS, OLEJNIK N etal.: Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab. Pharmacokinet. (2003) 18(2):128-138.
   PubMedGoogle Scholar
• KENWORTHY KE, BLOOMER JC, CLARKE SE, HOUSTON JB: CYP3A4 drug interactions: correlation of 10 invitro probe substrates. Br. J. Clin. Pharmacol. (1999) 48:716-727.
   PubMed Web of Science ®Google Scholar
• RILEY RJ, PARKER AJ, TRIGG S, MANNERS CN: Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm. Res. (2001) 18(5):652-655.
   PubMed Web of Science ®Google Scholar
• KALGUTKAR AS, TAYLOR TJ, VENKATAKRISHNAN K, ISIN EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos. (2003) 31(3):243-249.
   PubMed Web of Science ®Google Scholar
• SHEN L, FITZLOFF JF, COOK CS: Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos. (2004) 32(2):186-196.
   PubMed Web of Science ®Google Scholar
• EKINS S, STRESSER DM, WILLIAMSJA: Invitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. (2003) 24(4):161-166.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.gicare.com/pated/cimetidine.htm Jackson Gastroenterology Patient ed. (1998).
   Google Scholar
• http://www.promega.com/ Technical Resources, Promega Corp. website, see Technical Bulletin #325.
   Google Scholar
• http://www.promega.com/ Technical Resources, Promega Corp. website, see Technical Bulletin #340.
   Google Scholar
• http://www.invitrogen.com/content/sfs/manuals/O-13873-r1%20US%200405.pdf Vivid CYP450 screening kit protocols.
   Google Scholar
• http://www.bdbiosciences.com/discovery_labware/gentest Instruction manuals for high throughput P450 kits.
   Google Scholar
• http://www.bdbiosciences.com/discovery_labware/gentest/products/pdf/postindx.shtml STRESSER DM, TURNER SD, ACKERMANN JM, MILLER VP, CRESPICL: Fluorometric cytochromes P450 2C8, 2C9, and 2C19 inhibition assays: testing the one substrate paradigm. Poster.
   Google Scholar